Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.
Company Information
About this company
Key people
Orly Mishan
Independent Chairman of the Board
Todd Usen
Chief Executive Officer, Director
Deborah Kaster
Chief Business Officer
Sean M. Salmon
Director
James L. Cox
Independent Director
Sandra A. Gardiner
Independent Director
Keyvan Mirsaeedi-Farahani
Independent Director
Click to see more
Key facts
- Shares in issue22.21m
- EPICADGM
- ISINUS00534B1008
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$34.43m
- Employees41
- ExchangeNASDAQ
- Index
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.